Alpha-phenyl-N-tert-butylnitrone prevents oxidative stress in a haloperidol-induced animal model of tardive dyskinesia: investigating the behavioural and biochemical changes

Brain Research
Ritesh DayaRam K Mishra


Haloperidol (HP) is a widely prescribed antipsychotic drug used for the treatment of mental disorders. However, while providing therapeutic benefits, this drug also causes serious extrapyramidal side effects, such as tardive dyskinesia (TD). Upon chronic administration, HP causes behavioural supersensitivity to dopamine D2 receptor agonists, as well as the development of vacuous chewing movements (VCMs), in an animal model of human TD. Currently, a prevailing hypothesis to account for these behavioural abnormalities implicates oxidative stress. This study was undertaken to examine whether the free radical trapping agent, α-phenyl-N-tert-butylnitrone (PBN), can prevent the development of behavioural supersensitivity to dopamine D2 receptor agonists and the development of VCMs. Additionally, the study examined whether increased synthesis of apoptosis inducing factor (AIF) can result from HP-induced oxidative stress. Male Sprague-Dawley rats were treated with HP in conjunction with PBN, or its vehicle, for 4weeks. After a 24-hour washout period, behavioural observations were recorded along with the estimation of lipid peroxidation and antioxidant enzyme activities. The free radical trapping agent, PBN, prevented the development of...Continue Reading


Jan 1, 1979·European Journal of Pharmacology·S Chiu, Ram K Mishra
Jul 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·C N OliverR A Floyd
Jan 1, 1989·Progress in Neuro-psychopharmacology & Biological Psychiatry·S Wolfarth, K Ossowska
Oct 17, 1968·European Journal of Biochemistry·W G Niehaus, B Samuelsson
Nov 1, 1971·Analytical Biochemistry·C Beauchamp, I Fridovich
Jan 1, 1994·Neuroscience and Biobehavioral Reviews·J L Cadet, L A Kahler
Aug 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·G J LaHosteJ F Marshall
Jul 31, 1998·Progress in Neuro-psychopharmacology & Biological Psychiatry·H TakeuchiS Miura
Nov 13, 1998·The American Journal of Psychiatry·M G WoernerJ M Kane
Feb 10, 2000·Schizophrenia Bulletin·A M Elkashef, R J Wyatt
Nov 10, 2000·Pharmacopsychiatry·M Marsálek
Mar 10, 2001·Antioxidants & Redox Signaling·Y Kotake
Oct 27, 2001·The Journal of Infectious Diseases·J S BraunJ L Cleveland
May 1, 1959·Archives of Biochemistry and Biophysics·G L ELLMAN
Dec 20, 2003·Intensive Care Medicine·Yoanna K SkrobikStewart B Gottfried
Mar 11, 2006·Apoptosis : an International Journal on Programmed Cell Death·K J SkoblenickRam K Mishra
Jun 30, 2006·Journal of Neurochemistry·Barry Halliwell
Sep 4, 2008·Psychopharmacology·Shrinivas K KulkarniMahendra Bishnoi
Sep 3, 2009·Annals of the New York Academy of Sciences·Nicholas JozaGuido Kroemer
Feb 9, 2010·Trends in Biochemical Sciences·Emilie HangenNazanine Modjtahedi

Related Concepts

phenyl-N-tert-butylnitrone, (Z)-isomer
Catalase T
Lentiform Nucleus Structure
Cyclic N-Oxides
Dyskinesia, Medication-Induced
Reduced Glutathione
Stereotyped Behavior
Ag-Zn Superoxide Dismutase
Lipid Peroxidation

Related Feeds


Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here